Isoplexis’ Single-Cell Functional Phenotyping Platform Delivers Critical Predictive Metrics
Despite recent advancements in FDA approved therapeutics, Acute Myeloid Leukemia (AML) remains a difficult disease to treat, with few patients experiencing long-term remission.
In a recent paper published in Blood Advances, researchers conducted a Phase 2 trial for patients with relapsed/refractory(R/R) AML, who received a combination of azacytidine with the PD-1 checkpoint inhibitor, nivolumab.1 These patients showed promising response rates (33%) and median event-free and overall survival, compared to those treated with just azacytidine-based therapies. Furthermore, the combination azacytidine/nivolumab treatment was evaluated to have an acceptable safety profile.
In this study, a multiplexed immune assay was used to measure the functional states of CD4+ and CD8+ T cells at a single-cell level in pretherapy bone marrow in 16 patients with R/R AML treated with azacytidine/nivolumab. The team found that effector CD4+ T cells had distinct polyfunctional groups and were associated with positive responses and better outcomes, while CD8+ T cells did not have significant polyfunctionality or drug response.
Read the full article :
Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy.
Link : https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2021004583/477019/Single-cell-Polyfunctional-Proteomics-of-CD4-Cells
+1 (203) 208-4111 Mainsales@isoplexis.com Email
35 NE Industrial Rd